CL2007002668A1 - Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. - Google Patents

Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Info

Publication number: CL2007002668A1
Authority: CL; Chile
Prior art keywords: codifies; understands; joins; diabetes; treat
Prior art date: 2006-09-20

Application number

CL200702668A

Other languages

English (en)

Inventor

Hai Hu Shaw-Fen Sylvia Boo Yan

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-20

Filing date

2007-09-14

Publication date

2008-05-09

2007-09-14 Application filed by Amgen Inc filed Critical Amgen Inc

2008-05-09 Publication of CL2007002668A1 publication Critical patent/CL2007002668A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Epidemiology (AREA)

CL200702668A 2006-09-20 2007-09-14 Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. CL2007002668A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US84620206P	2006-09-20	2006-09-20
US96897707P	2007-08-30	2007-08-30

Publications (1)

Publication Number	Publication Date
CL2007002668A1 true CL2007002668A1 (es)	2008-05-09

Family

ID=39201088

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702668A CL2007002668A1 (es)	2006-09-20	2007-09-14	Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Country Status (19)

Country	Link
US (2)	US7947809B2 (es)
EP (1)	EP2074149B1 (es)
JP (1)	JP5513888B2 (es)
KR (1)	KR20090059161A (es)
CN (1)	CN101589062B (es)
AR (1)	AR062895A1 (es)
AU (1)	AU2007297652B2 (es)
BR (1)	BRPI0715017A8 (es)
CA (1)	CA2662613C (es)
CL (1)	CL2007002668A1 (es)
CR (1)	CR10736A (es)
EA (1)	EA200970262A1 (es)
ES (1)	ES2444012T3 (es)
IL (1)	IL197241A0 (es)
MX (2)	MX353319B (es)
NO (1)	NO20091534L (es)
PE (1)	PE20080846A1 (es)
TW (1)	TW200820985A (es)
WO (1)	WO2008036341A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR070844A1 (es) *	2008-03-27	2010-05-05	Lilly Co Eli	Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
WO2011030935A1 (en) *	2009-09-08	2011-03-17	Neopharm Co., Ltd.	Antibodies against glucagon receptor and their use
US8771696B2 (en)	2010-11-23	2014-07-08	Regeneron Pharmaceuticals, Inc.	Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar)	2010-11-23	2021-01-31	Regeneron Pharma	اجسام مضادة بشرية لمستقبلات الجلوكاجون
WO2013059531A1 (en) *	2011-10-20	2013-04-25	Genentech, Inc.	Anti-gcgr antibodies and uses thereof
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
JP6050671B2 (ja) *	2012-12-07	2016-12-21	ダイキン工業株式会社	空気調和装置の配管ユニットの製造方法および空気調和装置の施工方法
WO2014144817A2 (en)	2013-03-15	2014-09-18	Amgen Inc.	Inhibitory polypeptides specific to wnt inhibitors
WO2014181229A2 (en)	2013-05-07	2014-11-13	Rinat Neuroscience Corp.	Anti-glucagon receptor antibodies and methods of use thereof
CA2923145C (en)	2013-09-05	2025-09-16	Amgen Inc.	MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
CA3104268A1 (en) *	2014-04-10	2015-10-15	Obi Pharma Inc.	Antibodies, pharmaceutical compositions and uses thereof
MX377275B (es)	2014-05-16	2025-03-07	Amgen Inc	Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
EP3151855B1 (en) *	2014-06-08	2021-11-24	REMD Biotherapeutics, Inc.	Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
GB201410826D0 (en) *	2014-06-18	2014-07-30	Bergenbio As	Anti-axl antibodies
CA2963166C (en) *	2014-10-01	2023-10-03	Medimmune Limited	Antibodies to ticagrelor and methods of use
CN105669863B (zh) *	2014-12-05	2019-09-13	鸿运华宁（杭州）生物医药有限公司	一种能与人内皮素受体特异性结合的抗体及其应用
WO2016102657A1 (en)	2014-12-23	2016-06-30	Novo Nordisk A/S	Alpha-cell re-generation combined with conversion to beta cells
AR103442A1 (es)	2015-01-16	2017-05-10	Juno Therapeutics Inc	Anticuerpos y receptores de antígenos quiméricos específicos de ror1
KR20170138456A (ko)	2015-04-02	2017-12-15	렘드 바이로테라퓨틱스, 인크	글루카곤 수용체 길항 항체를 이용한 비만 및 비알콜성 지방간 질환 또는 비알콜성 지방간염의 치료 방법
CA2999747A1 (en)	2015-09-04	2017-03-09	Remd Biotherapeutics, Inc.	Methods for treating heart failure using glucagon receptor antagonistic antibodies
WO2017062693A1 (en) *	2015-10-07	2017-04-13	Remd Biotherapeutics, Inc.	Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies
KR101896882B1 (ko)	2015-11-30	2018-09-11	앱클론(주)	Vegfr2에 특이적으로 결합하는 항체
WO2017120261A1 (en) *	2016-01-04	2017-07-13	Remd Biotherapeutics, Inc.	Methods of treating type 2 diabetes mellitus using glucagon receptor antagonistic antibodies
WO2018027084A2 (en) *	2016-08-03	2018-02-08	Remd Biotherapeutics, Inc.	Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
JP7173962B2 (ja)	2016-08-30	2022-11-16	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法
US20190248888A1 (en)	2016-10-20	2019-08-15	Regeneron Pharmaceuticals, Inc.	Methods of lowering blood glucose levels
BR112019015479A2 (pt)	2017-01-27	2020-03-31	Ngm Biopharmaceuticals, Inc.	Anticorpo e seu uso, célula, composição, molécula polinucleotídica, vetor, método para inibir a sinalização de gcgr, método para reduzir ou baixar os níveis de glicose, método para aumentar o nível de peptídeo c, método para aumentar o nível de insulina, método para tratar diabetes, método para tratar hiperglicemia, método para tratar uma doença, método para melhorar a função das células
JP2020510646A (ja) *	2017-02-20	2020-04-09	ドラゴンフライセラピューティクス，インコーポレイテッド	Ｃｄ３３、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質
AU2018235928B2 (en)	2017-03-14	2023-09-21	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
CN107011414B (zh) *	2017-05-31	2020-04-24	浙江省农业科学院	具有降血糖功能的三肽spf及其用途
CA3071387A1 (en)	2017-08-22	2019-02-28	Regeneron Pharmaceuticals, Inc.	Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
CN119639849A (zh)	2018-03-26	2025-03-18	美国安进公司	细胞培养物中产生的抗体的总去岩藻糖基化糖型
CN110357959B (zh)	2018-04-10	2023-02-28	鸿运华宁（杭州）生物医药有限公司	Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US10961315B2 (en)	2018-07-27	2021-03-30	Ngm Biopharmaceuticals, Inc.	Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody
FI3852617T3 (fi)	2018-09-20	2025-10-21	Sfj Pharma X Inc	Vasta-ainefragmenttien käyttö tikagrelorin aktiivisuuden kääntämiseen
CA3123979A1 (en)	2018-12-21	2020-06-25	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific protein
US20220235140A1 (en) *	2019-05-29	2022-07-28	Hedgehog, Inc.	Antibody with enhanced binding affinity for endothelin receptor type a
MX2022001882A (es) *	2019-08-12	2022-05-30	Aptevo Res & Development Llc	Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
AU2020355251A1 (en)	2019-09-26	2022-04-21	Amgen Inc.	Methods of producing antibody compositions
WO2021247892A1 (en)	2020-06-04	2021-12-09	Amgen Inc.	Assessment of cleaning procedures of a biotherapeutic manufacturing process
US12391762B2 (en) *	2020-08-26	2025-08-19	Twist Bioscience Corporation	Methods and compositions relating to GLP1R variants
AU2021360897A1 (en)	2020-10-15	2023-05-25	Amgen Inc.	Relative unpaired glycans in antibody production methods
US20240067740A1 (en) *	2020-12-31	2024-02-29	Novarock Biotherapeutics, Ltd.	Antibodies to tnfr2 and uses thereof
WO2022182664A1 (en) *	2021-02-23	2022-09-01	10X Genomics, Inc.	A method for epitope binning of novel monoclonal antibodies
AR126089A1 (es)	2021-06-07	2023-09-13	Amgen Inc	Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
WO2023059607A1 (en)	2021-10-05	2023-04-13	Amgen Inc.	Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
AU2024256160A1 (en)	2023-04-20	2025-10-02	Amgen Inc.	Methods of determining relative unpaired glycan content
AU2024325342A1 (en)	2023-08-14	2026-02-26	Amgen Inc.	Methods for reducing yellow color
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2026090253A1 (en)	2024-10-23	2026-04-30	Amgen Inc.	Methods of determining glycan pairing content

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5776725A (en) *	1992-08-28	1998-07-07	Zymogenetics, Inc.	Recombinant production of glucagon receptors
US5639863A (en) *	1994-06-21	1997-06-17	Dan; Michael D.	Human monoclonal antibodies specific to cell cycle independent glioma surface antigen
US5889167A (en) *	1996-05-22	1999-03-30	Merck & Co., Inc.	Synthetic glucagon binding proteins
JP2001206899A (ja) *	1999-11-18	2001-07-31	Japan Tobacco Inc	ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
WO2002045494A2 (en)	2000-12-06	2002-06-13	Deltagen, Inc.	Transgenic mice containing glucagon receptor gene disruptions
US6864069B2 (en)	2001-10-05	2005-03-08	Bayer Pharmaceuticals Corporation	Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
ATE472556T1 (de) *	2002-12-02	2010-07-15	Amgen Fremont Inc	Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
WO2006005469A2 (en) *	2004-07-15	2006-01-19	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
ES2371083T3 (es) *	2004-12-21	2011-12-27	Medimmune Limited	Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
EP1851245B1 (en) *	2005-01-26	2012-10-10	Amgen Fremont Inc.	Antibodies against interleukin-1 beta

2007
- 2007-09-14 CL CL200702668A patent/CL2007002668A1/es unknown
- 2007-09-19 BR BRPI0715017A patent/BRPI0715017A8/pt not_active Application Discontinuation
- 2007-09-19 TW TW096134772A patent/TW200820985A/zh unknown
- 2007-09-19 JP JP2009529233A patent/JP5513888B2/ja active Active
- 2007-09-19 EP EP07852417.0A patent/EP2074149B1/en active Active
- 2007-09-19 MX MX2013003092A patent/MX353319B/es unknown
- 2007-09-19 AR ARP070104134A patent/AR062895A1/es active IP Right Grant
- 2007-09-19 MX MX2009003093A patent/MX2009003093A/es active IP Right Grant
- 2007-09-19 AU AU2007297652A patent/AU2007297652B2/en active Active
- 2007-09-19 WO PCT/US2007/020349 patent/WO2008036341A2/en not_active Ceased
- 2007-09-19 EA EA200970262A patent/EA200970262A1/ru unknown
- 2007-09-19 CN CN200780042973.XA patent/CN101589062B/zh active Active
- 2007-09-19 CA CA2662613A patent/CA2662613C/en active Active
- 2007-09-19 ES ES07852417.0T patent/ES2444012T3/es active Active
- 2007-09-19 KR KR1020097007922A patent/KR20090059161A/ko not_active Ceased
- 2007-09-20 PE PE2007001275A patent/PE20080846A1/es not_active Application Discontinuation
- 2007-09-20 US US11/903,481 patent/US7947809B2/en active Active
2009
- 2009-02-25 IL IL197241A patent/IL197241A0/en unknown
- 2009-04-17 NO NO20091534A patent/NO20091534L/no not_active Application Discontinuation
- 2009-04-17 CR CR10736A patent/CR10736A/es not_active Application Discontinuation
2011
- 2011-05-23 US US13/113,996 patent/US8158759B2/en active Active

Also Published As

Publication number	Publication date
AR062895A1 (es)	2008-12-10
KR20090059161A (ko)	2009-06-10
PE20080846A1 (es)	2008-08-23
IL197241A0 (en)	2011-08-01
ES2444012T3 (es)	2014-02-21
US8158759B2 (en)	2012-04-17
AU2007297652A1 (en)	2008-03-27
EP2074149B1 (en)	2013-11-06
CN101589062A (zh)	2009-11-25
NO20091534L (no)	2009-04-28
US20110223160A1 (en)	2011-09-15
TW200820985A (en)	2008-05-16
JP2010504331A (ja)	2010-02-12
JP5513888B2 (ja)	2014-06-04
CR10736A (es)	2009-06-30
WO2008036341A3 (en)	2009-02-05
AU2007297652B2 (en)	2012-02-16
BRPI0715017A8 (pt)	2018-04-03
US20090041784A1 (en)	2009-02-12
BRPI0715017A2 (pt)	2013-05-28
MX2009003093A (es)	2009-06-05
CA2662613A1 (en)	2008-03-27
WO2008036341A2 (en)	2008-03-27
EA200970262A1 (ru)	2009-10-30
CN101589062B (zh)	2014-08-20
US7947809B2 (en)	2011-05-24
EP2074149A2 (en)	2009-07-01
MX353319B (es)	2018-01-05
CA2662613C (en)	2014-01-28

Similar Documents

Publication	Publication Date	Title
WO2008121615A3 (en)	2008-12-04	Antibody formulation
CL2007002070A1 (es)	2008-02-08	Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
CL2013001279A1 (es)	2014-03-07	Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
BRPI0715017A8 (pt)	2018-04-03	composições e métodos relativos aos anticorpos receptores de glucagon
IL194550A (en)	2015-06-30	Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
CL2007002767A1 (es)	2008-05-30	Anticuerpo especifico para el receptor ccr5; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar enfermedades inmunosupresoras.
CL2013002062A1 (es)	2014-01-10	Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende: metodo de preparacion; y su uso para estimular la respuesta inmune.
CL2009000459A1 (es)	2010-12-10	Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
CL2007003623A1 (es)	2008-08-08	Proteina de enlace multivalente monocatenaria con funcion efectora; acido nucleico que la codifica; vector y celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y metodo para tratar trastornos proliferativos.
PT2380592T (pt)	2018-06-06	Anticorpos antagonistas dirigidos contra o péptido relacionado com o gene da calcitonina e métodos utilizando os mesmos
CL2008000935A1 (es)	2008-11-07	Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
CL2013001468A1 (es)	2014-03-21	Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre.
CL2014001334A1 (es)	2014-12-19	Una proteina de union, anticuerpos o fragmentos del mismo que se une a her-3; molecula de acido nucleico que la codifica; procedimiento de produccion; composicion farmaceutica que lo comprende ; su uso para tratar enfermedades asociadas a her -3; y metodo de diagnostico de una enfermedad (div. sol. 3748-2006).
CL2013001121A1 (es)	2014-03-07	Acido ribonucleico interferente; polinucleotido que lo codifica; construccion de adn que lo codifica; celula huesped; composicion que lo comprende; y su uso para la prevencion y/o control de la infestacion por plaga.
CL2007001840A1 (es)	2008-01-18	Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de adn que lo codifica; vector y celula huesped que la comprenden; proceso de produccion; preparacion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de patologias mediadas por il-17.
CL2009000586A1 (es)	2010-06-04	Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
CL2008000479A1 (es)	2008-08-22	Peptido de glucagon no nativo; composicion farmaceutica que lo comprende; y metodo para tratar la hipoglucemia y diabetes.
CL2007003807A1 (es)	2008-05-09	Anticuerpos humanos anti-cd44 o fragmentos de los mismos; acidos nucleicos que los codifican; vector y celula huesped que los comprende; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar los sintomas de trastornos mediado
CL2008000839A1 (es)	2008-09-26	Anticuerpo anti-ige/m1'; acido nucleico que lo codifica; vector y celula huesped; proceso de produccion; composicion que comprende al anticuerpo; y su uso para tratar trastornos mediados por ige.
CL2007003794A1 (es)	2008-06-27	Anticuerpo anti-receptor del factor de crecimiento insulinico i (igf-ir); polinucleotido que lo codifica; metodo de produccion; composicion que lo comprende; y su uso para tratar cancer.
BRPI0722062A2 (pt)	2014-04-01	Anticorpos contra receptor do fator de crescimento i semelhante à insulina e usos dos mesmos
CL2007002835A1 (es)	2008-05-30	Anticuerpo monoclonal especifico para el receptor cxcr4; acido nucleico que lo codifica; vector y celula que lo comprenden; metodo de produccion; inmunoconjugado y composicion que lo comprende; y su uso para tratar cancer, trastornos inflamatorios y
CL2007003303A1 (es)	2008-06-27	Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
CL2013000369A1 (es)	2014-08-08	Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2013000843A1 (es)	2014-03-07	Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.